Author: Prisco, Sasha Z.; Thenappan, Thenappan; Prins, Kurt W.
Title: Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension Cord-id: domvoa2g Document date: 2020_12_28
ID: domvoa2g
Snippet: Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. Although there are shared molecular mechanisms in both RV and left ventricle (LV) dysfunction, there are important differences between the 2 ventricles that may allow for the development of RV-enhancing or RV-directed therapies. In this review, we discuss the current understandings of the dysregulated pathway
Document: Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. Although there are shared molecular mechanisms in both RV and left ventricle (LV) dysfunction, there are important differences between the 2 ventricles that may allow for the development of RV-enhancing or RV-directed therapies. In this review, we discuss the current understandings of the dysregulated pathways that promote RV dysfunction, highlight RV-enriched or RV-specific pathways that may be of particular therapeutic value, and summarize recent and ongoing clinical trials that are investigating RV function in PAH. It is hoped that development of RV-targeted therapies will improve quality of life and enhance survival for this deadly disease.
Search related documents:
Co phrase search for related documents- a1 adrenergic receptor and a1 receptor: 1
- a1 receptor and long term outcome: 1
- active trial and lung disease: 1
- administration expression and lung disease: 1, 2
- long term outcome and lung disease: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date